Valley Forge’s clinical contract research organization Indipharm is being re-launched as InClinica by its new owner, Velocity Fund Partners, writes John George for the Philadelphia Business Journal.

Jim Nolan, operating partner of Velocity Fund Partners, will serve as CEO of the newly re-branded InClinica. Dr. Edward J. Brennan Jr., founder and president of Indipharm, is taking over as Chief Medical Officer, while Michael Fare becomes the COO and Chief Technology Officer.

In addition to its Valley Forge-area headquarters, InClinica also has offices in the United Kingdom, Israel, and Malaysia. The organization works across all phases of clinical development for new drug products, as well as medical devices. Financial terms of the agreement were not disclosed.

“InClinica’s existing global footprint and experience in early drug and device development and clinical trials, combined with Velocity’s experience and contacts in both healthcare and life sciences, will enable us to provide companies with significant value in all clinical phases,” said Ken Melani, managing partner of Velocity Fund Partners and chairman of InClinica.

Read more about the changes at Indipharm in the Philadelphia Business Journal by clicking here.

_______
Top photo credit: Laboratory Equipment in Science Research Lab via photopin (license)